Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of Inhaled AZD4604 in Healthy Volunteers and Mild Asthma
NCT04769869Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of londamocitinib in asthma (8 arms), sponsored by AstraZeneca. Primary endpoints: Number of healthy volunteers/patients with adverse events (AEs) at Day 16, Maximum observed plasma (peak) drug concentration and 5 more. Started Jul 2022; status: completed.
02
Drugs
londamocitinib
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04769869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04769869.